During the past decade, Santa Casa de Misericordia de Belo Horizonte conducted 39 clinical trials. In the 10-year time frame, 39 clinical trials started and 26 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 16 clinical trials were completed. i.e. 69.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Santa Casa de Misericordia de Belo Horizonte" #1 sponsor was "Hoffmann-La Roche" with 9 trials, followed by "Janssen Research & Development, LLC" with 9 trials sponsored, "Astellas Pharma Inc" with 3 trials sponsored, "Eurofarma Laboratorios S.A." with 3 trials sponsored and "Janssen Vaccines & Prevention B.V." with 3 trials sponsored. Other sponsors include 27 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Santa Casa de Misericordia de Belo Horizonte" #1 collaborator was "Ministry of Health, Brazil" with 3 trials as a collaborator, "Basilea Pharmaceutica International Ltd" with 2 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator, "Basilea Pharmaceutica" with 1 trials as a collaborator and "Canadian Institutes of Health Research (CIHR)" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Santa Casa de Misericordia de Belo Horizonte" are "Systemic Lupus Erythematosus" (4 trials), "Influenza" (3 trials), "Aspergillosis" (2 trials), "COVID-19" (2 trials) and "Cardiovascular Diseases" (2 trials). Many other conditions were trialed in "Santa Casa de Misericordia de Belo Horizonte" in a lesser frequency.

Most popular intervention types in "Santa Casa de Misericordia de Belo Horizonte" are "Drug" (48 trials), "Other" (13 trials), "Biological" (5 trials), "Device" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (23 trials), "Ad26.COV2.S" (3 trials), "Ocrelizumab" (3 trials), "Baloxavir Marboxil" (2 trials) and "Baricitinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Santa Casa de Misericordia de Belo Horizonte" are 59 trials for "All" genders.

Currently, there are NaN active trials in "Santa Casa de Misericordia de Belo Horizonte". undefined are not yet recruiting, 11 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 31 completed trials in Santa Casa de Misericordia de Belo Horizonte, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Santa Casa de Misericordia de Belo Horizonte, 3 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 38 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".